254 related articles for article (PubMed ID: 29568395)
21. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
Wu WC; Chen MH
Front Oncol; 2022; 12():1031396. PubMed ID: 36703785
[TBL] [Abstract][Full Text] [Related]
22. A rare case of recurrent ovarian cancer with
Endo Y; Watanabe T; Saito M; Saito K; Suzuki R; Sano H; Natori Y; Sasaki E; Ueda M; Kamo N; Furukawa S; Soeda S; Kono K; Saji S; Fujimori K
Mol Clin Oncol; 2022 Apr; 16(4):90. PubMed ID: 35251641
[No Abstract] [Full Text] [Related]
23. Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy.
Chu P; Batson S; Hodgson M; Mitchell CR; Steenrod A
Future Oncol; 2020 Feb; 16(4):61-74. PubMed ID: 31942815
[No Abstract] [Full Text] [Related]
24. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R; Hofmann NE; Smith B; Odintsov I; Vojnic M; Linkov I; Tam A; Khodos I; Mattar MS; de Stanchina E; Flynn D; Ladanyi M; Drilon A; Shinde U; Davare MA
Commun Biol; 2020 Dec; 3(1):776. PubMed ID: 33328556
[TBL] [Abstract][Full Text] [Related]
25. [Study of
Zhang HD; Yin XN; Cai ZL; Zhang B
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):769-774. PubMed ID: 34530557
[TBL] [Abstract][Full Text] [Related]
26. Case report:
Lazzari C; Pecciarini L; Doglioni C; Pedica F; Gajate AMS; Bulotta A; Gregorc V; Cangi MG
Front Oncol; 2022; 12():1038774. PubMed ID: 36419889
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of a novel
Milione M; Ardini E; Christiansen J; Valtorta E; Veronese S; Bosotti R; Pellegrinelli A; Testi A; Pietrantonio F; Fucà G; Wei G; Murphy D; Siena S; Isacchi A; De Braud F
Oncotarget; 2017 Aug; 8(33):55353-55360. PubMed ID: 28903424
[TBL] [Abstract][Full Text] [Related]
28. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
[TBL] [Abstract][Full Text] [Related]
29. Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services.
Walker A
J Oncol Pharm Pract; 2020 Dec; 26(8):2015-2019. PubMed ID: 32957860
[TBL] [Abstract][Full Text] [Related]
30. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
31. NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report.
Palmerini E; Frega G; Gambarotti M; Frisoni T; Cesari M; Bazzocchi A; Miceli M; Donati DM; Fanti S; Nanni C; Benini S; Longhi A; Paioli A; Marrari A; Hakim R; Righi A; Ibrahim T
Front Oncol; 2023; 13():1252359. PubMed ID: 37876963
[TBL] [Abstract][Full Text] [Related]
32. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Murray BW; Rogers E; Zhai D; Deng W; Chen X; Sprengeler PA; Zhang X; Graber A; Reich SH; Stopatschinskaja S; Solomon B; Besse B; Drilon A
Mol Cancer Ther; 2021 Dec; 20(12):2446-2456. PubMed ID: 34625502
[No Abstract] [Full Text] [Related]
33. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Farago AF; Taylor MS; Doebele RC; Zhu VW; Kummar S; Spira AI; Boyle TA; Haura EB; Arcila ME; Benayed R; Aisner DL; Horick NK; Lennerz JK; Le LP; Iafrate AJ; Ou SI; Shaw AT; Mino-Kenudson M; Drilon A
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30215037
[TBL] [Abstract][Full Text] [Related]
34. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
Jin W; Yun C; Hobbie A; Martin MJ; Sorensen PH; Kim SJ
Cancer Res; 2007 Apr; 67(7):3192-200. PubMed ID: 17409427
[TBL] [Abstract][Full Text] [Related]
35. Case report: Adult NTRK-rearranged spindle cell neoplasms with TPM3-NTRK1 fusion in the pelvic.
Cao Q; Huang Z; Liang H; Hu X; Wang L; Yang Y; Lian B; Huang J; Guo J
Front Oncol; 2024; 14():1308916. PubMed ID: 38357202
[TBL] [Abstract][Full Text] [Related]
36. A review of NTRK fusions in cancer.
Manea CA; Badiu DC; Ploscaru IC; Zgura A; Bacinschi X; Smarandache CG; Serban D; Popescu CG; Grigorean VT; Botnarciuc V
Ann Med Surg (Lond); 2022 Jul; 79():103893. PubMed ID: 35860155
[TBL] [Abstract][Full Text] [Related]
37. ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse models.
Schmid S; Russell ZR; Yamashita AS; West ME; Parrish AG; Walker J; Rudoy D; Yan JZ; Quist DC; Gessesse BN; Alvinez N; Cimino PJ; Kumasaka DK; Parchment RE; Holland EC; Szulzewsky F
bioRxiv; 2024 Mar; ():. PubMed ID: 38558981
[TBL] [Abstract][Full Text] [Related]
38. NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine.
Zito Marino F; Pagliuca F; Ronchi A; Cozzolino I; Montella M; Berretta M; Errico ME; Donofrio V; Bianco R; Franco R
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466202
[TBL] [Abstract][Full Text] [Related]
39. Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.
Lanman T; Hayden Gephart M; Bui N; Toland A; Nagpal S
Case Rep Oncol; 2021; 14(3):1841-1846. PubMed ID: 35111018
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of targeted therapy resistance in a pediatric glioma driven by
Keddy C; Neff T; Huan J; Nickerson JP; Beach CZ; Akkari Y; Ji J; Moore S; Nazemi KJ; Corless CL; Beadling C; Woltjer R; Cho YJ; Wood MD; Davare MA
Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34429303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
